Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #21526 on iBio Inc (IBIO)
$Parabolic2030?$
03/19/20 4:14 PM
#21528 RE: Ezpenny #21526
ttottip
03/19/20 4:28 PM
#21530 RE: Ezpenny #21526
TheFinalCD
03/19/20 4:43 PM
#21531 RE: Ezpenny #21526
The aggregate service fees payable to the Company for the first phase of services to be provided by the Company relating to the Company’s proposal for the development of a Plant-Made Rituximab and in consideration for providing the technology transfer contemplated in the MDJA is approximately $4.7 million. Such amount was previously omitted from the version of the MJDA filed with the Original Report. Although the Company has determined to disclose such information, other information which is not material and would likely cause competitive harm to the Company if publicly disclosed, has been omitted from Exhibit 10.1 filed herewith.